Atezolizumab (anti-PD-L1)

製品コード：A2004         Batch: A200408

印刷

Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.

製品説明

CAS No. 1380723-44-3
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 4.4mg/ml
Endotoxin Level ＜1EU/mg

カスタマーフィードバック

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

[ Int Immunopharmacol, 2024, ] PubMed: 38442580
Pivotal role of myeloid-derived suppressor cells in infection-related tumor growth [ Cancer Med, 2024, 13(4):e6917] PubMed: 38457241
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN [ Research Square, 2024, 10.21203/rs.3.rs-3782509/v1] PubMed: none
Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy [ J Extracell Vesicles, 2023, 12(11):e12379] PubMed: 37974395
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer [ Cell Death Dis, 2023, 14(9):636] PubMed: 37752152
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer [ Cell Death Dis, 2023, 14(9):636] PubMed: 37752152
Synergistically Enhancing Immunotherapy Efficacy in Glioblastoma with Gold-Core Silica-Shell Nanoparticles and Radiation [ Int J Nanomedicine, 2023, 18:7677-7693] PubMed: 38111846
Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells [ Front Immunol, 2023, 14:1229341] PubMed: 37638041
ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma [ J Transl Med, 2023, 21(1):341] PubMed: 37217923
Self-assembled albumin nanoparticles induce pyroptosis for photodynamic/photothermal/immuno synergistic therapies in triple-negative breast cancer [ Front Immunol, 2023, 14:1173487] PubMed: 37342347

人間や獣医の診断であるか治療的な使用のためにでない。